查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2003038

細胞活力檢測市場：按產品類型、檢測方法、應用和最終用戶分類－2026-2032年全球市場預測

Cell Viability Assays Market by Product Type, Detection Method, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，細胞活力檢測市場價值將達到 22.2 億美元，到 2026 年將成長至 24.8 億美元，到 2032 年將達到 48.5 億美元，年複合成長率為 11.77%。

主要市場統計數據
基準年 2025 22.2億美元
預計年份：2026年 24.8億美元
預測年份 2032 48.5億美元
複合年成長率 (%) 11.77%

闡明細胞活力檢測在研究、診斷和工業領域中的關鍵作用，並指導技術採用和操作整合。

細胞活力檢測廣泛應用於生命科學的各個領域，從基礎細胞生物學到臨床前藥物研發。在學術界、臨床診斷以及工業研發中，這些檢測方法都是細胞健康、增殖以及對外部干擾反應的關鍵指標。實現細胞活力評估的技術和儀器構成了一個相互依存的生態系統。檢測方法的化學處理、檢測平台和分析軟體協同工作，共同決定了其處理能力、靈敏度以及對特定實驗環境的適用性。

變革性的變化重塑了檢測技術、儀器和數據整合實踐。

在細胞活力領域，多項技術變革正在交匯融合，重新定義實驗室測量和解讀細胞健康狀況的方式。檢測化學的進步實現了非侵入式測量，並拓寬了動態範圍。同時，儀器製造商越來越注重模組化、易於自動化的平台，這些平台可以與液體處理系統結合。此外，軟體和分析技術也正從簡單的資料收集轉向支援品管、標準化和進階下游分析的整合流程。這種發展使得研究團隊能夠從孤立的終點測量轉向更豐富、更具時間序列性和情境感知的資料集。

美國關稅政策在2025年對供應鏈韌性與籌資策略的累積影響

近期關稅調整進一步加劇了檢測試劑盒、儀器和輔助試劑採購計畫的複雜性。雖然直接影響因供應商所在地和產品類別而異，但各組織正透過供應商多元化和重新評估總到岸成本（而非僅僅關注單價）來應對。這項調整促使採購團隊使採購合約更具柔軟性，並探索近岸外包和區域分銷中心等風險緩解策略。

基於細分市場的洞察，指導策略定位，重點關注產品類型、檢測方法、最終用戶和應用的優先性。

從市場區隔的觀點解讀市場，有助於釐清創新與需求的交會點。依產品類型分類，市場可分為檢測試劑盒、儀器和軟體，其中檢測試劑盒可細分為比色試劑盒、螢光盒和發光試劑盒。每類產品都有其獨特的價值提案。檢測試劑盒提供檢驗、針對特定實驗環境最佳化的化學反應；儀器提供檢測精度和處理能力；軟體則透過數據處理和分析整合這些要素。

影響美洲、歐洲、中東和非洲以及亞太地區招募和投資模式的區域趨勢和策略挑戰。

地理趨勢對實驗室技術的應用、監管和支援有顯著影響。在美洲，強大的學術生態系統和成熟的生物製藥中心推動了對多功能檢測平台的需求，這些平台能夠同時支援藥物發現和轉化研究。在該地區，能夠與現有自動化系統整合並提供強大的本地技術支援以維持高通量工作流程連續性的系統往往更受青睞。

來自競爭對手和合作夥伴的見解，突顯了透過創新、服務和整合解決方案實現策略差異化的重要性。

在競爭激烈的市場環境中，能夠將經過驗證的試劑與相容的儀器和分析工具相結合，從而提供一致且基於實證的工作流程的公司，擁有競爭優勢。策略差異化通常源自於檢驗化學領域的技術創新、優先考慮通量和最低維護成本的儀器性能，以及能夠簡化資料完整性和監管可追溯性的軟體。那些明確致力於開放、整合框架並發布可靠的檢驗資料集的公司，往往能夠更快地被要求提供可驗證效能的機構買家所接受。

為產業領導者提供以差異化、韌性和以客戶為中心的解決方案為重點的實用策略建議。

領導企業應優先考慮端到端驗證方案，以減輕買家的焦慮並加快檢查室部署。投資於互通性和開放式整合，有助於在自動化和連接複用工作流程中實現更廣泛的應用；而允許分階段升級的模組化硬體設計則有助於維護長期的客戶關係。在營運方面，加強區域服務基礎設施並實踐透明的供應鏈實踐，可以降低採購風險並增強客戶信心。

嚴謹的調查方法，強調一手檢驗、跨部門三角測量和方法論的透明記錄。

本研究途徑結合了對技術領導者、採購專家和最終用戶的訪談，以及對同行評審文獻和公開監管指南的二次分析。主要研究著重於了解用例需求、採購和營運挑戰，以及對檢測效能驗證的期望。二次研究評估了檢測化學、儀器可靠性報告以及支持可重複性和合規性的軟體功能集的調查方法趨勢。

結論：為了推動科學成果的取得，我們必須優先考慮技術能力與檢查室營運需求的策略性匹配。

細胞活力檢測生態系統正透過化學、檢測平台和數據分析的互補性改進而不斷發展。如今，檢查室尋求的解決方案不僅要具備卓越的技術性能，還要確保操作可靠性，並能與現有工作流程無縫整合。因此，成功的供應商往往能夠提供檢驗且可互通的產品和服務，並透過完善的服務和培訓為客戶提供支援。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：細胞活力檢測市場：依產品類型分類

  • 檢測試劑盒
    • 顏色對比套件
    • 螢光測量試劑盒
    • 發光套件
  • 裝置
  • 軟體

第9章：依檢測方法分類的細胞活力檢測市場

  • 化學冷光
  • 比色法
  • 螢光法
    • 鈣黃綠素AM
    • 萊札茲林
  • 發光法
    • ATP
    • 螢光素酶

第10章：細胞活力檢測市場：依應用領域分類

  • 基礎研究
  • 細胞增殖研究
  • 細胞毒性試驗
  • 藥物篩檢

第11章：細胞活力檢測市場：依最終用戶分類

  • 學術和研究機構
  • 合約研究機構
  • 醫院和診斷中心
  • 製藥和生物技術公司

第12章：細胞活力檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：細胞活力偵測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：細胞活力檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國細胞活力檢測市場

第16章：中國細胞活力檢測市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AAT Bioquest, Inc.
  • Abcam PLC
  • Agilent Technologies, Inc.
  • Akadeum Life Sciences
  • Assay Genie
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Biotium, Inc.
  • BMG LABTECH GmbH
  • Cell Biolabs, Inc.
  • Creative Bioarray
  • Danaher Corporation
  • Elabscience Biotechnology Inc.
  • Enzo Life Sciences, Inc.
  • F. Hoffmann-La Roche AG
  • GE HealthCare Technologies, Inc.
  • Hemogenix Inc.
  • Illumina, Inc
  • Merck KGaA
  • Miltenyi Biotec BV & Co. KG
  • PerkinElmer, Inc.
  • Promega Corporation
  • Qiagen NV
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-957C47F94DCB

The Cell Viability Assays Market was valued at USD 2.22 billion in 2025 and is projected to grow to USD 2.48 billion in 2026, with a CAGR of 11.77%, reaching USD 4.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.22 billion
Estimated Year [2026] USD 2.48 billion
Forecast Year [2032] USD 4.85 billion
CAGR (%) 11.77%

Framing the critical role of cell viability assays across research, diagnostics, and industry to guide technology adoption and operational alignment

Cell viability assays underpin a broad spectrum of life sciences activities, ranging from foundational cell biology to preclinical drug discovery. Across academia, clinical diagnostics, and industrial R&D, these assays serve as critical indicators of cellular health, proliferation, and response to perturbations. The techniques and instruments that enable viability assessment form an interdependent ecosystem: assay chemistries, detection platforms, and analytical software together determine throughput, sensitivity, and suitability for specific experimental contexts.

As organizations pursue higher throughput, more physiologically relevant models, and streamlined workflows, decision-makers must balance technical performance with operational constraints such as sample throughput, reproducibility, and integration into automated pipelines. This introduction situates cell viability assays within that broader operational and strategic frame, highlighting the need for cross-functional alignment between scientists, procurement leads, and technology evaluators. With innovations reshaping the available toolset, clarity on assay selection logic and deployment scenarios becomes indispensable for teams seeking to optimize experimental design and accelerate translational outcomes.

Transformative Shifts Reshaping Assay Technologies, Instrumentation, and Data Integration Practices

The cell viability arena is experiencing a confluence of technological shifts that are redefining how laboratories measure and interpret cellular health. Advances in detection chemistries have driven noninvasive readouts and expanded dynamic range, while instrument manufacturers increasingly prioritize modular, automation-friendly platforms that can be paired with liquid-handling systems. At the same time, software and analytics are moving from basic readout collection toward integrated pipelines that support quality control, normalization, and sophisticated downstream analyses. This evolution allows teams to move from isolated endpoint measurements to richer longitudinal and context-aware datasets.

In parallel, methodological trends emphasize compatibility with complex biological models such as 3D cultures and co-culture systems, which place higher demands on sensitivity and signal specificity. Researchers are also adopting multiplexed workflows that combine viability readouts with phenotypic or molecular endpoints, increasing the value of interoperable hardware and data standards. Consequently, purchasers and laboratory leaders must reassess procurement criteria to prioritize platforms that offer flexible detection modalities, validated reagent chemistry, and robust software ecosystems. Taken together, these transformative shifts favor suppliers who present coherent end-to-end solutions that reduce integration burden and accelerate reproducibility in diverse experimental settings.

Cumulative Effects of United States Tariff Policies in 2025 on Supply Chain Resilience and Procurement Strategies

Recent tariff adjustments have introduced additional complexity into procurement planning for assay kits, instruments, and ancillary reagents. Though the immediate effects vary by supplier origin and product classification, organizations have responded by diversifying supplier portfolios and by reassessing total landed cost rather than focusing solely on unit price. This recalibration has prompted procurement teams to build greater flexibility into sourcing contracts and to evaluate nearshoring or regional distribution hubs as risk mitigation strategies.

Manufacturers and distributors have adapted by optimizing logistics, consolidating shipments, and exploring alternative sourcing pathways to preserve delivery timelines. Meanwhile, laboratory operations are increasingly factoring customs and import variability into reagent safety stock levels and experiment scheduling. In response, some purchasers prioritize vendors with established regional service networks and validated quality management systems to reduce downtime risk. As a result, strategic procurement decisions now emphasize supplier transparency, predictable lead times, and contractual mechanisms that share tariff-related risk, enabling scientific teams to maintain continuity in experimental programs without compromising on assay performance or compliance requirements.

Segmentation-Driven Insight into Product Types, Detection Methods, End Users, and Application Priorities That Inform Strategic Positioning

Interpreting the market through a segmentation lens clarifies where innovation and demand converge. Based on product type, the landscape encompasses assay kits, instruments, and software, with assay kits themselves differentiated into colorimetric kits, fluorometric kits, and luminescent kits. Each product class presents distinct value propositions: assay kits deliver validated chemistries optimized for specific experimental contexts, instruments provide detection fidelity and throughput, and software ties these elements together through data handling and analysis.

Examining detection methods, common approaches include chemiluminescent, colorimetric, fluorometric, and luminescent modalities. Within fluorometric workflows, fluorescent probes such as Calcein AM and Resazurin are frequently selected for live-cell compatibility and multiplexing potential. Luminescent approaches leverage ATP-based chemistries and luciferase systems to yield highly sensitive endpoints with low background; these detection differences influence assay choice based on sample type, dynamic range needs, and downstream analytics. End-user segments include academic and research institutions, contract research organizations, hospitals and diagnostic centers, and pharmaceutical and biotechnology companies, each bringing distinct priorities around throughput, regulatory compliance, and integration with drug discovery or clinical pipelines. Application-focused use cases span basic research, cell proliferation studies, cytotoxicity testing, and drug screening, which in turn shape the required assay sensitivity, reproducibility, and compatibility with cellular models.

Together, these segmentation dimensions reveal where suppliers can differentiate through product modularity, validation packages for specific applications, and software that streamlines data interpretation across detection chemistries. Understanding the intersection of product type and end-user need enables more targeted value propositions, whether that means positioning luminescent kits for high-sensitivity screening or promoting fluorometric reagents and instruments for live-cell, multiplexed assays. In this way, segmentation insight supports product development prioritization, channel strategy, and customer engagement frameworks that align to the technical and operational realities of diverse laboratory environments.

Regional Dynamics and Strategic Imperatives Across the Americas, Europe, Middle East & Africa, and Asia-Pacific That Influence Adoption and Investment Patterns

Geographic dynamics materially influence how technologies are adopted, regulated, and supported in laboratory settings. In the Americas, strong academic ecosystems and established biopharma hubs drive demand for versatile assay platforms that can support both discovery research and translational studies. This region often prioritizes systems that integrate with existing automation and that offer robust local technical support to maintain continuity in high-throughput workflows.

In Europe, Middle East & Africa, regulatory harmonization and a diverse set of research infrastructures encourage suppliers to provide validated protocols and adaptable solutions that can serve both centralized laboratories and distributed clinical sites. Service networks and regional distribution models matter greatly for mission-critical reagent stability and instrument uptime. In the Asia-Pacific region, rapid expansion in biotechnology and contract research capacity is accelerating uptake of scalable, cost-efficient assay solutions. Manufacturers that deliver localized training, supply continuity, and software that accommodates multilingual and region-specific compliance requirements tend to gain traction quickly. Across all regions, strategic imperatives include aligning service models with local laboratory practices, investing in regional inventory strategies to mitigate cross-border friction, and tailoring go-to-market approaches to the distinct procurement behaviors and regulatory contexts that shape adoption.

Competitive and Collaborative Company Insights That Highlight Strategic Differentiation Through Innovation, Service, and Integrated Offerings

The competitive landscape rewards firms that combine validated reagents with compatible instruments and analytics to deliver cohesive, evidence-backed workflows. Strategic differentiation often emerges from technical innovation in assay chemistry, from instrument features that prioritize throughput and minimal maintenance, and from software that simplifies data integrity and regulatory traceability. Companies that make clear commitments to open integration frameworks and that publish robust validation datasets tend to accelerate adoption among institutional purchasers who require demonstrable performance.

Collaboration between reagent manufacturers, instrument developers, and software providers has become more prevalent as customers seek turnkey solutions that reduce internal integration costs. Service excellence, training programs, and localized technical support are equally important, particularly for clinical laboratories and contract research organizations that require consistent, reproducible outputs. Finally, strategic partnerships with model providers and academic centers can validate novel assay approaches and expand use-case breadth, reinforcing a vendor's reputation as a reliable partner for both exploratory research and regulated applications.

Actionable Strategic Recommendations for Industry Leaders Focused on Differentiation, Resilience, and Customer-Centric Solutions

Leaders should prioritize end-to-end validation packages that reduce buyer uncertainty and accelerate laboratory adoption. Investing in cross-compatibility and open integration can unlock broader adoption within automated and multiplexed workflows, while modular hardware designs that allow incremental upgrades help preserve long-term customer relationships. From an operational perspective, enhancing regional service capabilities and transparent supply chain practices will mitigate procurement risk and reinforce customer confidence.

Commercial strategies should emphasize consultative selling that aligns assay capabilities with specific application needs such as cytotoxicity testing or high-throughput drug screening. Providing applied training, application notes, and reproducibility datasets will shorten adoption cycles and strengthen customer retention. Finally, companies should pursue selective partnerships with model providers and academic labs to validate new assay formats and to expand the evidence base supporting performance claims, thereby positioning themselves as trusted collaborators in translational science.

Rigorous Research Methodology Emphasizing Primary Validation, Cross-Functional Triangulation, and Transparent Documentation of Methods

The research approach combines primary interviews with technical leaders, procurement specialists, and end users alongside secondary analysis of peer-reviewed literature and publicly available regulatory guidance. Primary engagement focused on eliciting use-case requirements, pain points in procurement and operation, and validation expectations for assay performance. Secondary review assessed methodological trends in detection chemistries, instrument reliability reporting, and software feature sets that support reproducibility and compliance.

Triangulation across these inputs enabled synthesis of thematic findings and identification of actionable recommendations. All methodological choices, including interview protocols, sample selection rationale, and analytical frameworks, are documented to promote reproducibility and to allow informed evaluation of the evidence base. Where applicable, methodological limitations are disclosed, and interpretive caution is recommended for extrapolations beyond reviewed contexts.

Conclusion Emphasizing Strategic Alignment Between Technology Capabilities and Laboratory Operational Needs to Drive Scientific Outcomes

The cell viability assays ecosystem is evolving through complementary improvements in chemistries, detection platforms, and data analytics. Laboratories now demand solutions that deliver not only technical performance but also operational reliability and seamless integration with existing workflows. Consequently, successful providers are those that present validated, interoperable offerings and that support customers with robust service and training.

Moving forward, stakeholders who align technology selection with specific application requirements-whether basic research, proliferation studies, cytotoxicity testing, or drug screening-will reduce experimental risk and accelerate translational progress. Strategic procurement, resilient supply chain planning, and evidence-driven vendor selection remain central to converting assay capability into measurable scientific and commercial outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell Viability Assays Market, by Product Type

  • 8.1. Assay Kits
    • 8.1.1. Colorimetric Kits
    • 8.1.2. Fluorometric Kits
    • 8.1.3. Luminescent Kits
  • 8.2. Instruments
  • 8.3. Software

9. Cell Viability Assays Market, by Detection Method

  • 9.1. Chemiluminescent
  • 9.2. Colorimetric
  • 9.3. Fluorometric
    • 9.3.1. Calcein AM
    • 9.3.2. Resazurin
  • 9.4. Luminescent
    • 9.4.1. ATP
    • 9.4.2. Luciferase

10. Cell Viability Assays Market, by Application

  • 10.1. Basic Research
  • 10.2. Cell Proliferation Studies
  • 10.3. Cytotoxicity Testing
  • 10.4. Drug Screening

11. Cell Viability Assays Market, by End User

  • 11.1. Academic And Research Institutions
  • 11.2. Contract Research Organizations
  • 11.3. Hospitals And Diagnostic Centers
  • 11.4. Pharmaceutical And Biotechnology Companies

12. Cell Viability Assays Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cell Viability Assays Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cell Viability Assays Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Cell Viability Assays Market

16. China Cell Viability Assays Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AAT Bioquest, Inc.
  • 17.6. Abcam PLC
  • 17.7. Agilent Technologies, Inc.
  • 17.8. Akadeum Life Sciences
  • 17.9. Assay Genie
  • 17.10. Becton, Dickinson and Company
  • 17.11. Bio-Rad Laboratories, Inc.
  • 17.12. Bio-Techne Corporation
  • 17.13. Biotium, Inc.
  • 17.14. BMG LABTECH GmbH
  • 17.15. Cell Biolabs, Inc.
  • 17.16. Creative Bioarray
  • 17.17. Danaher Corporation
  • 17.18. Elabscience Biotechnology Inc.
  • 17.19. Enzo Life Sciences, Inc.
  • 17.20. F. Hoffmann-La Roche AG
  • 17.21. GE HealthCare Technologies, Inc.
  • 17.22. Hemogenix Inc.
  • 17.23. Illumina, Inc
  • 17.24. Merck KGaA
  • 17.25. Miltenyi Biotec B.V. & Co. KG
  • 17.26. PerkinElmer, Inc.
  • 17.27. Promega Corporation
  • 17.28. Qiagen N.V.
  • 17.29. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL VIABILITY ASSAYS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CELL VIABILITY ASSAYS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CELL VIABILITY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CELL VIABILITY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY COLORIMETRIC KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY COLORIMETRIC KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY COLORIMETRIC KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY CHEMILUMINESCENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY CHEMILUMINESCENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY CHEMILUMINESCENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY COLORIMETRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY COLORIMETRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY COLORIMETRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY CALCEIN AM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY CALCEIN AM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY CALCEIN AM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY RESAZURIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY RESAZURIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY RESAZURIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY ATP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY ATP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY ATP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY LUCIFERASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY LUCIFERASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY LUCIFERASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY CELL PROLIFERATION STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY CELL PROLIFERATION STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY CELL PROLIFERATION STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY CYTOTOXICITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY CYTOTOXICITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY CYTOTOXICITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY DRUG SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY DRUG SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY DRUG SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS CELL VIABILITY ASSAYS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GCC CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GCC CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 152. GCC CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 153. GCC CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2032 (USD MILLION)
  • TABLE 154. GCC CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2032 (USD MILLION)
  • TABLE 155. GCC CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. GCC CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. G7 CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. G7 CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. G7 CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 176. G7 CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 177. G7 CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2032 (USD MILLION)
  • TABLE 178. G7 CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2032 (USD MILLION)
  • TABLE 179. G7 CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. G7 CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. NATO CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. NATO CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 184. NATO CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 185. NATO CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2032 (USD MILLION)
  • TABLE 186. NATO CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2032 (USD MILLION)
  • TABLE 187. NATO CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. NATO CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL CELL VIABILITY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES CELL VIABILITY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA CELL VIABILITY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA CELL VIABILITY ASSAYS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA CELL VIABILITY ASSAYS MARKET SIZE, BY ASSAY KITS, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA CELL VIABILITY ASSAYS MARKET SIZE, BY DETECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA CELL VIABILITY ASSAYS MARKET SIZE, BY FLUOROMETRIC, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA CELL VIABILITY ASSAYS MARKET SIZE, BY LUMINESCENT, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA CELL VIABILITY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA CELL VIABILITY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)